top of page
With 600+ videos, our free oncology education content provides healthcare providers ample opportunity to gain insightful information as well as CME/CE credits and MOC points.
Breast Cancer Content
Role of Genetic Testing in Black Breast Cancer Patients: 2023 Diversity Dinner Memphis
Aimee Martin, MS, CGC from West Cancer Center comments on using genetic testing in Black breast cancer patients: Earlier diagnosis, triple negative cancers, and more aggressive disease linked to BRCA 1/2 gene mutations.
Preserving Fertility, and Genomic Assays in Breast Cancer: 2023 KU Breast Cancer Year in Review
Dr Willaim Gradishar, MD, from Northwestern University Feinberg School of Medicine comments on strategies to retain fertility in young women with breast cancer, and the use of genomic assays to better assess the need for chemotherapy.
On the Role of Molecular Tumor Profiling in Breast Cancer: 2023 KU Breast Cancer Year in Review
Dr Lajos Pusztai, MD, DPhil from Yale School of Medicine comments on the use of molecular tumor profiling in breast cancer: Finding actionable, targetable mutations in PI3K, ESR, BRCA, and others; ctDNA monitoring for molecular recurrence in early breast cancer.
Hot Topics for Case Discussion in Breast Cancer: 2023 KU Breast Cancer Year in Review
Dr Priyanka Sharma, MD from University of Kansas Cancer Center comments on current hot topics for case discussion in breast cancer: Emerging therapies for endocrine-resistant disease, defining HER-2 Low breast cancer, and re-evaluating treatment in triple negative disease.
Radiation After Lumpectomy – Determining Who Benefits: 2023 KU Breast Cancer Year in Review
Dr Julia White, MD from University of Kansas Cancer Center comments on emerging technologies to determine who benefits from radiation therapy benefit after lumpectomy: Biologic selectors, multi-gene assays, and the POLAR gene assay.
Historical Perspective on HR+/HER2- Breast Cancer: 2023 KU Breast Cancer Year in Review
Dr Joyce O’Shaughnessy, MD from Texas Oncology discusses on the evolution of treatment for HR+/HER2- breast cancer: From tamoxifen, to aromatase inhibitors, to CDK 4/6 inhibitors, and inhibitors of endocrine therapy resistance.
Breast Cancer Molecular Testing – More Tools in the Toolbox: 2023 KU Breast Cancer Year in Review
Dr Jennifer Klemp, PhD, MPH, MA, from University of Kansas Cancer Center comments on the expanding use of molecular testing in breast cancer: More options available to help guide treatment, and learning how best to apply them.